Discussion about this post

User's avatar
Modern Discontent's avatar

So as mentioned in the SARS-COV1 study Sotrovimab was a monoclonal antibody that was isolated from someone previously infected with SARS-COV1. It was effective until Ba.2, likely from the T376A, D405N, and R408S group of mutations. These amino acids aren't on the surface, and so I believe it's assumed that these mutations led to a different folding pattern in the spike that shielded Sortrovimab's epitopes and stopped it from binding.

Expand full comment
Graham (baba gbb)'s avatar

Brian - Seriously, God bless you. You are doing such incredibly important work, laying out the biochemical architecture of what is happening on earth in similar fashion to Katherine Watt revealing the legal architecture. I do not fully understand all your analysis. But I understand enough to see how true your aim is and how committed you are to both accuracy and precision. Please know you are deeply appreciated.

Expand full comment
12 more comments...

No posts